ReviewJournal of the American Heart Association2026
Targeting the Myocardial Microenvironment: Novel Antiviral Strategies and Therapeutic Perspectives for Coxsackievirus B-Induced Myocarditis.
Review in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus B3 is a primary cause of viral myocarditis, with ≈20% of cases progressing to dilated cardiomyopathy. Despite its clinical significance, therapeutic strategies remain limited. The pathogenesis of coxsackievirus B3-induced myocarditis is complex, centered on the virus's ability to hijack the myocardial microenvironment, which is composed of various cell types and their interactions, influencing disease progression and outcomes. This review comprehensively summarizes the changes in fibroblasts, endothelial cells, mast cells, monocytes/macrophages, neutrophils, dendritic cells, natural killer cells, and lymphocytes within the myocardial microenvironment during coxsackievirus B3 infection, highlighting their critical roles in disease development. Additionally, it provides an overview of recent findings on potential therapeutic approaches targeting the myocardial microenvironment. Targeted regulation of cellular functions, key molecular pathway intervention, intelligent delivery system development, and noninvasive biomarker identification, combined with organoid and artificial intelligence technologies, pave the way for precision therapy and diagnosis centered on myocardial microenvironment remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.